We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
SUPN vs. TEVA: Which Stock Should Value Investors Buy Now?
Read MoreHide Full Article
Investors with an interest in Medical - Generic Drugs stocks have likely encountered both Supernus Pharmaceuticals (SUPN - Free Report) and Teva Pharmaceutical Industries Ltd. (TEVA - Free Report) . But which of these two stocks is more attractive to value investors? We'll need to take a closer look to find out.
The best way to find great value stocks is to pair a strong Zacks Rank with an impressive grade in the Value category of our Style Scores system. The proven Zacks Rank puts an emphasis on earnings estimates and estimate revisions, while our Style Scores work to identify stocks with specific traits.
Supernus Pharmaceuticals has a Zacks Rank of #1 (Strong Buy), while Teva Pharmaceutical Industries Ltd. has a Zacks Rank of #4 (Sell) right now. Investors should feel comfortable knowing that SUPN likely has seen a stronger improvement to its earnings outlook than TEVA has recently. But this is just one piece of the puzzle for value investors.
Value investors analyze a variety of traditional, tried-and-true metrics to help find companies that they believe are undervalued at their current share price levels.
Our Value category highlights undervalued companies by looking at a variety of key metrics, including the popular P/E ratio, as well as the P/S ratio, earnings yield, cash flow per share, and a variety of other fundamentals that have been used by value investors for years.
SUPN currently has a forward P/E ratio of 16.70, while TEVA has a forward P/E of 17.08. We also note that SUPN has a PEG ratio of 0.61. This popular metric is similar to the widely-known P/E ratio, with the difference being that the PEG ratio also takes into account the company's expected earnings growth rate. TEVA currently has a PEG ratio of 3.58.
Another notable valuation metric for SUPN is its P/B ratio of 2.64. The P/B is a method of comparing a stock's market value to its book value, which is defined as total assets minus total liabilities. By comparison, TEVA has a P/B of 5.16.
These metrics, and several others, help SUPN earn a Value grade of B, while TEVA has been given a Value grade of C.
SUPN is currently sporting an improving earnings outlook, which makes it stick out in our Zacks Rank model. And, based on the above valuation metrics, we feel that SUPN is likely the superior value option right now.
View the Zacks #1 Rank List
Image: Bigstock
SUPN vs. TEVA: Which Stock Should Value Investors Buy Now?
Investors with an interest in Medical - Generic Drugs stocks have likely encountered both Supernus Pharmaceuticals (SUPN - Free Report) and Teva Pharmaceutical Industries Ltd. (TEVA - Free Report) . But which of these two stocks is more attractive to value investors? We'll need to take a closer look to find out.
The best way to find great value stocks is to pair a strong Zacks Rank with an impressive grade in the Value category of our Style Scores system. The proven Zacks Rank puts an emphasis on earnings estimates and estimate revisions, while our Style Scores work to identify stocks with specific traits.
Supernus Pharmaceuticals has a Zacks Rank of #1 (Strong Buy), while Teva Pharmaceutical Industries Ltd. has a Zacks Rank of #4 (Sell) right now. Investors should feel comfortable knowing that SUPN likely has seen a stronger improvement to its earnings outlook than TEVA has recently. But this is just one piece of the puzzle for value investors.
Value investors analyze a variety of traditional, tried-and-true metrics to help find companies that they believe are undervalued at their current share price levels.
Our Value category highlights undervalued companies by looking at a variety of key metrics, including the popular P/E ratio, as well as the P/S ratio, earnings yield, cash flow per share, and a variety of other fundamentals that have been used by value investors for years.
SUPN currently has a forward P/E ratio of 16.70, while TEVA has a forward P/E of 17.08. We also note that SUPN has a PEG ratio of 0.61. This popular metric is similar to the widely-known P/E ratio, with the difference being that the PEG ratio also takes into account the company's expected earnings growth rate. TEVA currently has a PEG ratio of 3.58.
Another notable valuation metric for SUPN is its P/B ratio of 2.64. The P/B is a method of comparing a stock's market value to its book value, which is defined as total assets minus total liabilities. By comparison, TEVA has a P/B of 5.16.
These metrics, and several others, help SUPN earn a Value grade of B, while TEVA has been given a Value grade of C.
SUPN is currently sporting an improving earnings outlook, which makes it stick out in our Zacks Rank model. And, based on the above valuation metrics, we feel that SUPN is likely the superior value option right now.